Cyclacel Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Bio Green Med Solution

03/03/2023 14:35

* Cyclacel Pharmaceuticals Inc  CYCC.OQ   CYCC.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 6. 
    * 
    * ​Refinitiv's mean analyst estimate for Cyclacel
Pharmaceuticals
Inc is for a loss of 48 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $16.5​, above​ its last closing price
of $0.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.55       -0.56      -0.42     Beat    25.4
 Jun. 30 2022  -0.61       -0.63      -0.46     Beat    26.4
 Mar. 31 2022  -0.69       -0.68      -0.42     Beat    38.6​
 Dec. 31 2021              -0.65      -0.54     Beat    17.3
 ​​Sep.        -0.64       -0.65      -0.54     Beat    16.9
 30 2021                                                
 Jun. 30 2021  -0.51       -0.50      -0.56     Missed  -12.8​
 Mar. 31 2021  -0.48       -0.49      -0.50     Missed  -2.7
 Dec. 31 2020  -0.51       -0.51      -1.34     Missed  -160.2
 This summary was machine generated March 3 at 14:35 GMT.  All
figures in US dollars  unless otherwise stated